Reduction of atrial fibrillation by Tanshinone IIA in chronic heart failure

Related Experiment Video

Updated: Mar 12, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.9K

Zhifeng He1, Changzheng Sun2, Yi Xu2

  • 1Department of Thoracic Cardiovascular, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|November 17, 2016
PubMed

Insights

Tanshinone IIA (TAN) reduces atrial fibrillation (AF) in chronic heart failure (CHF) models. It prolongs atrial refractoriness and conduction time, offering antiarrhythmic benefits.

Area of Science:

  • Cardiology
  • Pharmacology
  • Electrophysiology

Background:

  • Chronic heart failure (CHF) is associated with increased risk of atrial fibrillation (AF).
  • Understanding the electrophysiological mechanisms of AF in CHF is crucial for developing effective treatments.
  • Tanshinone IIA (TAN) is a compound with potential antiarrhythmic properties.

Purpose of the Study:

  • To investigate the antiarrhythmic effect of TAN on AF prevention in a CHF experimental model.
  • To elucidate the electrophysiological mechanisms underlying TAN's antiarrhythmic effects in the atrium.

Main Methods:

  • Chronic heart failure (CHF) was induced in rabbits via rapid ventricular pacing.
  • Isolated hearts were perfused using the Langendorff method.
  • Atrial electrophysiological parameters, including action potential duration (aAPD) and effective refractory period (aERP), were measured. AF was induced using burst pacing and pharmacological agents.

Main Results:

  • CHF hearts exhibited prolonged aAPD and aERP compared to sham controls.
  • TAN administration significantly reduced AF inducibility in both sham and CHF hearts (50% reduction).
  • TAN increased aERP, prolonging atrial post-repolarization refractoriness, and moderately increased interatrial conduction time without affecting aAPD.

Conclusions:

  • TAN demonstrates efficacy in reducing AF inducibility in an experimental model of CHF.
  • The antiarrhythmic effect of TAN is attributed to the prolongation of atrial post-repolarization refractoriness and increased interatrial conduction time.
Keywords:
Atrial fibrillationChronic heart failurePost-repolarization refractorinessTanshinone IIA

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
455
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
494
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K